Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta-analysis.

ABSTRACT:

Background

To systematically evaluate the safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis.

Materials and methods

Randomized controlled trials (RCTs) of Deucravacitinib for moderate to severe plaque psoriasis in PubMed, Cochrane Library, Embase, and Web of Science were searched from database establishment to April 2023. Literature quality was independently evaluated by two investigators using the Cochrane risk-of-bias assessment tool, and the systematic analysis was made using StateSE15 and RevMan 5.3 software.

Results

Four RCTs were included, including 1751 patients with moderate to severe plaque psoriasis. Meta-analysis showed that the differences in efficacy and adverse events (AEs) between the Deucravacitinib group and placebo group w

SUBMITTER: Hu C 

PROVIDER: S-EPMC11344170 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature